Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Abstract 5768: Identifying signaling changes that give rise to drug resistance in acute myeloid leukemia through multiomic modeling across diverse model systems

Juan Camilo Posso, Setareh Sharzehi, Marina A. Gritsenko, McKenna Finley, Chelsea M. Hutchinson-Bunch, Keith Beadle, Karl K. Weitz, Melissa Stewart, Samantha A. Obermiller, Belinda B. Garana, Anupriya Agarwal, Cristina Tognon, Jeffrey Tyner, Paul D. Piehowski, Elie Traer, Sara J. Gosline

Cancer Res (2025) 85 (8_Supplement_1): 5768.

https://doi.org/10.1158/1538-7445.AM2025-5768

Published: 21 April 2025

View articletitled, Abstract 5768: Identifying signaling changes that give rise to drug resistance in acute myeloid leukemia through multiomic modeling across diverse model systems

Journal Articles

Abstract 3749: Multi-Omic Characterization of Treatment-Naive Acute Myeloid Leukemia Reveals Subtype-Specific Features and Biomarkers of Drug Response

Cancer Res (2025) 85 (8_Supplement_1): 3749.

https://doi.org/10.1158/1538-7445.AM2025-3749

Published: 21 April 2025

View articletitled, Abstract 3749: Multi-Omic Characterization of Treatment-Naive Acute Myeloid Leukemia Reveals Subtype-Specific Features and Biomarkers of Drug Response

Journal Articles

Abstract 1844: Proteomic characterization of decitabine resistance in acute myeloid leukemia reveals signaling pathway crosstalk dampens the effectiveness of combination therapy

James C. Pino, Camilo Posso, Setareh Sharzehi, Sara Gosline, Chelsea Hutchinson-Bunch, Elie Traer, Paul D. Piehowski, Karin D. D. Rodland, Jeffrey W. Tyner, Tao Liu, Anupriya Agarwal

Cancer Res (2024) 84 (6_Supplement): 1844.

https://doi.org/10.1158/1538-7445.AM2024-1844

Published: 22 March 2024

View articletitled, Abstract 1844: Proteomic characterization of decitabine resistance in acute myeloid leukemia reveals signaling pathway crosstalk dampens the effectiveness of combination therapy

Journal Articles

Abstract 7354: Proteogenomic and metabolomic characterization of acute myeloid leukemia

Cancer Res (2024) 84 (6_Supplement): 7354.

https://doi.org/10.1158/1538-7445.AM2024-7354

Published: 22 March 2024

View articletitled, Abstract 7354: Proteogenomic and metabolomic characterization of acute myeloid leukemia

Journal Articles

Abstract 3172: Mapping the molecular landscape of acute myeloid leukemia enables prediction of drug response from proteogenomic data

Cancer Res (2023) 83 (7_Supplement): 3172.

https://doi.org/10.1158/1538-7445.AM2023-3172

Published: 04 April 2023

View articletitled, Abstract 3172: Mapping the molecular landscape of acute myeloid leukemia enables prediction of drug response from proteogenomic data

Journal Articles

Abstract LT022: The AML microenvironment catalyzes a step-wise evolution to gilteritinib resistance

Sunil K. Joshi, Tamilla Nechiporuk, Daniel Bottomly, Paul Piehowski, Julie A. Reisz, Janét Pittsenbarger, Andy Kaempf, Sara J.C. Gosline, Yi-Ting Wang, Tao Liu, Cristina E. Tognon, Angelo D’Alessandro, Jeffrey W. Tyner, Shannon K. McWeeney, Karin D. Rodland, Brian J. Druker, Elie Traer

Cancer Res (2021) 81 (5_Supplement): LT022.

https://doi.org/10.1158/1538-7445.TME21-LT022

Published: 01 March 2021

View articletitled, Abstract LT022: The AML microenvironment catalyzes a step-wise evolution to gilteritinib resistance

Journal Articles

Abstract 926: Extrinsic and intrinsic activation of RAS/MAPK signaling enables resistance to FLT3 inhibitor, gilteritinib, in acute myeloid leukemia

Sunil K. Joshi, Stephen Christy, Renata Scopim Ribeiro, Shannon McWeeney, Jeffrey W. Tyner, Cristina E. Tognon, Brian J. Druker, Elie Traer

Cancer Res (2019) 79 (13_Supplement): 926.

https://doi.org/10.1158/1538-7445.AM2019-926

Published: 01 July 2019

View articletitled, Abstract 926: Extrinsic and intrinsic activation of RAS/MAPK signaling enables resistance to FLT3 inhibitor, gilteritinib, in acute myeloid leukemia

Journal Articles

FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

Elie Traer, Jacqueline Martinez, Nathalie Javidi-Sharifi, Anupriya Agarwal, Jennifer Dunlap, Isabel English, Tibor Kovacsovics, Jeffrey W. Tyner, Melissa Wong, Brian J. Druker

Cancer Res (2016) 76 (22): 6471–6482.

https://doi.org/10.1158/0008-5472.CAN-15-3569

Published: 14 November 2016

View articletitled, FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

Includes: Supplementary data

Journal Articles

Abstract 1631: FGF2 activation of FGFR1 in head and neck squamous cell carcinoma is associated with more invasive disease and can be attenuated by FGFR inhibition

Isabel A. English, Jacqueline Martinez, Edward El Rassi, Mark Schmidt, Ellen Langer, Sophia Bornstein, John Gleysteen, Melissa Wong, Brian Druker, Elie Traer

Cancer Res (2016) 76 (14_Supplement): 1631.

https://doi.org/10.1158/1538-7445.AM2016-1631

Published: 15 July 2016

View articletitled, Abstract 1631: FGF2 activation of FGFR1 in head and neck squamous cell carcinoma is associated with more invasive disease and can be attenuated by FGFR inhibition

Journal Articles

Abstract 984: FGF2 from the bone marrow promotes resistance to FLT3 inhibitors in AML

Jacqueline Martinez, Elie Traer, Nathalie Javidi-Sharifi, Anupriya Agarwal, Jennifer Dunlap, Isabel English, Tibor Kovacsovics, Jeffrey Tyner, Melissa Wong, Brian Druker

Cancer Res (2015) 75 (15_Supplement): 984.

https://doi.org/10.1158/1538-7445.AM2015-984

Published: 01 August 2015

View articletitled, Abstract 984: FGF2 from the bone marrow promotes resistance to FLT3 inhibitors in AML

Journal Articles

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance

Nathalie Javidi-Sharifi, Elie Traer, Jacqueline Martinez, Anu Gupta, Takehiro Taguchi, Jennifer Dunlap, Michael C. Heinrich, Christopher L. Corless, Brian P. Rubin, Brian J. Druker, Jeffrey W. Tyner

Cancer Res (2015) 75 (5): 880–891.

https://doi.org/10.1158/0008-5472.CAN-14-0573

Published: 01 March 2015

View articletitled, Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance

Includes: Supplementary data

Journal Articles

Abstract 5248: Targeted suppression of interleukin-1 signaling inhibits growth of primary human acute myeloid leukemia cells

Anupriya Agarwal, Alyssa Carey, Elie Traer, Jeffrey Tyner, Grover C. Bagby, Brian J. Druker

Cancer Res (2014) 74 (19_Supplement): 5248.

https://doi.org/10.1158/1538-7445.AM2014-5248

Published: 01 October 2014

View articletitled, Abstract 5248: Targeted suppression of interleukin-1 signaling inhibits growth of primary human acute myeloid leukemia cells

Journal Articles

Abstract 4971: FGF2 promotes resistance to ABL kinase inhibitors in CML.

Elie Traer, Nathalie Javidi-Sharifi, Anupriya Agarwal, Jennifer Dunlap, Jeffrey Tyner, Melissa Wong, Brian Druker

Cancer Res (2013) 73 (8_Supplement): 4971.

https://doi.org/10.1158/1538-7445.AM2013-4971

Published: 15 April 2013

View articletitled, Abstract 4971: FGF2 promotes resistance to ABL kinase inhibitors in CML.

Journal Articles

The Inducible Prostaglandin Biosynthetic Enzyme, Cyclooxygenase 2, Is Not Mutated in Patients with Attenuated Adenomatous Polyposis Coli

Lisa N. Spirio, Dan A. Dixon, Jennifer Robertson, Margaret Robertson, Jalene Barrows, Elie Traer, Randall W. Burt, Mark F. Leppert, Ray White, Stephen M. Prescott

Cancer Res (1998) 58 (21): 4909–4912.

Published: 01 November 1998

View articletitled, The Inducible Prostaglandin Biosynthetic Enzyme, Cyclooxygenase 2, Is Not Mutated in Patients with Attenuated Adenomatous Polyposis Coli

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 5768: Identifying signaling changes that give rise to drug resistance in acute myeloid leukemia through multiomic modeling across diverse model systems

Abstract 3749: Multi-Omic Characterization of Treatment-Naive Acute Myeloid Leukemia Reveals Subtype-Specific Features and Biomarkers of Drug Response

Abstract 1844: Proteomic characterization of decitabine resistance in acute myeloid leukemia reveals signaling pathway crosstalk dampens the effectiveness of combination therapy

Abstract 7354: Proteogenomic and metabolomic characterization of acute myeloid leukemia

Abstract 3172: Mapping the molecular landscape of acute myeloid leukemia enables prediction of drug response from proteogenomic data

Abstract LT022: The AML microenvironment catalyzes a step-wise evolution to gilteritinib resistance

Abstract 926: Extrinsic and intrinsic activation of RAS/MAPK signaling enables resistance to FLT3 inhibitor, gilteritinib, in acute myeloid leukemia

FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

Abstract 1631: FGF2 activation of FGFR1 in head and neck squamous cell carcinoma is associated with more invasive disease and can be attenuated by FGFR inhibition

Abstract 984: FGF2 from the bone marrow promotes resistance to FLT3 inhibitors in AML

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance

Abstract 5248: Targeted suppression of interleukin-1 signaling inhibits growth of primary human acute myeloid leukemia cells

Abstract 4971: FGF2 promotes resistance to ABL kinase inhibitors in CML.

The Inducible Prostaglandin Biosynthetic Enzyme, Cyclooxygenase 2, Is Not Mutated in Patients with Attenuated Adenomatous Polyposis Coli

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only